MILAGEN, INC., heralded by its slogan, "Advancing Health Care Through Diagnostics", is a late-stage, pre-commercial diagnostic company established in 1997. The company is poised to transform the healthcare sector by developing and commercializing non-invasive, in vitro diagnostic (IVD) products aimed at meeting significant clinical demands in cancer prevention, detection, diagnosis, and management. Its proprietary antibody-based blood serum assays promise breakthroughs, particularly in detecting Breast and Colon cancer recurrence.
Despite its longstanding presence, the company is undergoing a critical transition towards commercialization, with preparations underway for a major clinical study designed for early cancer detection. The last substantial financial backing was a €3.08M Series B investment led by Auriga Partners in 2003, highlighting a significant gap since their last funding round. This evolving stage presents both an opportunity and a challenge for potential investors eyeing substantial innovations in the Health Care industry.
